Item 6. EXHIBITS

Exhibits (listed by number corresponding to the Exhibit Table of Item 601 in Regulation S-K).


Exhibit No.						Description
31a.						Section 302 Certification Letter (filed herewith).
31b.						Section 302 Certification Letter (filed herewith).
32a.						Section 906 Certification Letter (furnished herewith).
32b.						Section 906 Certification Letter (furnished herewith).
101.INS						Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH						Inline XBRL Taxonomy Extension Schema Document.
101.CAL						Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF						Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB						Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE						Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104						Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

Indicates, in this Quarterly Report on Form 10-Q, brand names of products, which are registered trademarks not solely owned by the Company or its subsidiaries. Gleevec is a trademark of Novartis AG; Keytruda is a trademark of Merck & Co., Inc., Rahway, NJ, USA; Plavix is a trademark of Sanofi; and Tecentriq is a trademark of Genentech, Inc. Brand names of products that are in all italicized letters, without an asterisk, are registered trademarks of BMS and/or one of its subsidiaries.

SUMMARY OF ABBREVIATED TERMS

Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol Myers Squibb, BMS, the Company, we, our or us in this Quarterly Report on Form 10-Q, unless the context otherwise indicates. Throughout this Quarterly Report on Form 10-Q we have used terms which are defined below:


2024 Form 10-K	Annual Report on Form 10-K for the fiscal year ended December 31, 2024	Mirati	Mirati Therapeutics, Inc.
2024 Senior Unsecured Notes	Aggregate principal amount of $13.0 billion of senior unsecured notes issued by BMS in February 2024	MPM	malignant pleural mesothelioma
2seventy bio	2seventy bio, Inc.	MSI-H	microsatellite instability-high
aGVHD	acute graft-versus-host disease	MTA	Methylthioadenosine
ADC	antibody-drug conjugate	MZL	marginal zone lymphoma
ADP	adenosine diphosphate	NDA	New Drug Application
ANDA	Abbreviated New Drug Application	nHCM	Nonobstructive Hypertrophic Cardiomyopathy
AOCI	Accumulated other comprehensive loss	NHL	Non-Hodgkin's Lymphoma
AstraZeneca	AstraZeneca PLC	NKT	natural killer T
BCMA	B-cell maturation antigen-directed	NSCLC	non-small cell lung cancer
BioArctic	BioArctic AB	NTRK	Neurotrophic Tropomyosin Receptor Kinase
BioNTech	BioNTech SE	Nimbus	Nimbus Therapeutics
CAR-T	chimeric antigen receptor T-cell	NVAF	non-valvular atrial fibrillation
Celgene	Celgene Corporation	OBBBA	One Big Beautiful Bill Act
CERCLA	U.S. Comprehensive Environmental Response, Compensation and Liability Act	OECD	Organization for Economic Co-operation and Development
CGDP	Coverage Gap Discount Program	oHCM	Obstructive Hypertrophic Cardiomyopathy
CHMP	Committee for Medicinal Products for Human Use	Ono	Ono Pharmaceutical Co., Ltd
CLL	Chronic Lymphocytic Leukemia	ORR	overall response rate
CML	chronic myeloid leukemia	PD-1	programmed cell death protein 1
CRC	colorectal cancer	PD-L1	programmed death-ligand 1
CTLA4	Cytotoxic T-lymphocyte Antigen-4	PDUFA	Prescription Drug User Fee Act
CVR	Contingent value right	PE	pulmonary embolism
DLBCL	Diffuse Large B-cell Lymphoma	Philochem	Philochem AG
dMMR	mismatch repair deficient	PRMT5	protein arginine methyltransferase 5
DVT	deep vein thrombosis	PsA	psoriatic arthritis
EC	European Commission	Quarterly Report on Form 10-Q	Quarterly Report on Form 10-Q for the quarter ended September 30, 2025
EMA	European Medicines Agency	R&D	research and development
EPS	earnings per share	RA	rheumatoid arthritis
ES-SCLC	extensive stage small cell lung cancer	RayzeBio	RayzeBio, Inc.
EU	European Union	RCC	renal cell carcinoma
Exchange Act	the Securities Exchange Act of 1934	RDFV	readily determinable fair values
FASB	Financial Accounting Standards Board	REMS	risk evaluation and mitigation strategy
FDA	U.S. Food and Drug Administration	RNA	ribonucleic acid
FL	follicular lymphoma	Roche	F. Hoffman-La Roche & Co.
GAAP	generally accepted accounting principles	RPT	radiopharmaceutical therapeutics
GTN	gross-to-net	RRMM	relapsed or refractory multiple myeloma
HCC	hepatocellular carcinoma	RS	ring sideroblast
HCM	hypertrophic cardiomyopathy	Sanofi	Sanofi S.A.
HHS	Health and Human Services	sBLA	supplemental biologics license application
IND	investigational new drug	SEC	U.S. Securities and Exchange Commission
IPRD	in-process research and development	SLL	Small Lymphocytic Lymphoma
IRA	Inflation Reduction Act of 2022	SPC	Supplementary Protection Certificate
IRS	Internal Revenue Service	SystImmune	SystImmune, Inc.
JIA	juvenile idiopathic arthritis	TCJA	Tax Cuts and Jobs Act of 2017
Karuna	Karuna Therapeutics, Inc.	TNBC	triple negative breast cancer
KRAS	Kirsten rat sarcoma	UC	ulcerative colitis
LBCL	Large B-cell Lymphoma	UK	United Kingdom
LNP	lipid nanoparticle	U.S.	United States
MCL	mantle cell lymphoma	VAT	value added tax
MDS	myelodysplastic syndromes	VEGF-A	Vascular endothelial growth factor A
Merck	Merck & Co.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		BRISTOL-MYERS SQUIBB COMPANY (REGISTRANT)

Date:	October 30, 2025	By:	/s/ Christopher Boerner, Ph.D.
			Christopher Boerner, Ph. D. Chair of the Board and Chief Executive Officer

Date:	October 30, 2025	By:	/s/ David V. Elkins
			David V. Elkins Chief Financial Officer

Previous: Item 5. OTHER INFORMATION